Pharmacokinetics of maropitant citrate in New Zealand White rabbits (Oryctolagus cuniculus)

Sarah M. Ozawa, Michelle G. Hawkins, Tracy L. Drazenovich, Philip H. Kass, Heather K. Knych

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus). ANIMALS: 11 sexually intact (3 males and 8 females) adult rabbits. PROCEDURES: Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored. RESULTS: Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3%. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.

Original languageEnglish (US)
Pages (from-to)963-968
Number of pages6
JournalAmerican journal of veterinary research
Volume80
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

New Zealand White rabbit
Oryctolagus cuniculus
citrates
pharmacokinetics
Pharmacokinetics
rabbits
injection site
Rabbits
intravenous injection
Injections
adverse effects
gastrointestinal motility
pharmacology
half life
bioavailability
Gastrointestinal Motility
Body Water
urine
maropitant
injection

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetics of maropitant citrate in New Zealand White rabbits (Oryctolagus cuniculus). / Ozawa, Sarah M.; Hawkins, Michelle G.; Drazenovich, Tracy L.; Kass, Philip H.; Knych, Heather K.

In: American journal of veterinary research, Vol. 80, No. 10, 01.10.2019, p. 963-968.

Research output: Contribution to journalArticle

@article{0a171c85639641cf823971ef9d123798,
title = "Pharmacokinetics of maropitant citrate in New Zealand White rabbits (Oryctolagus cuniculus)",
abstract = "OBJECTIVE: To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus). ANIMALS: 11 sexually intact (3 males and 8 females) adult rabbits. PROCEDURES: Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored. RESULTS: Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3{\%}. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.",
author = "Ozawa, {Sarah M.} and Hawkins, {Michelle G.} and Drazenovich, {Tracy L.} and Kass, {Philip H.} and Knych, {Heather K.}",
year = "2019",
month = "10",
day = "1",
doi = "10.2460/ajvr.80.10.963",
language = "English (US)",
volume = "80",
pages = "963--968",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetics of maropitant citrate in New Zealand White rabbits (Oryctolagus cuniculus)

AU - Ozawa, Sarah M.

AU - Hawkins, Michelle G.

AU - Drazenovich, Tracy L.

AU - Kass, Philip H.

AU - Knych, Heather K.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - OBJECTIVE: To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus). ANIMALS: 11 sexually intact (3 males and 8 females) adult rabbits. PROCEDURES: Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored. RESULTS: Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3%. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.

AB - OBJECTIVE: To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus). ANIMALS: 11 sexually intact (3 males and 8 females) adult rabbits. PROCEDURES: Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored. RESULTS: Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3%. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=85072681525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072681525&partnerID=8YFLogxK

U2 - 10.2460/ajvr.80.10.963

DO - 10.2460/ajvr.80.10.963

M3 - Article

C2 - 31556710

AN - SCOPUS:85072681525

VL - 80

SP - 963

EP - 968

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 10

ER -